Transposon Therapeutics receives ARPA-H award for TPN-101
The up to $22M funding supports studying TPN-101 to extend healthspan under the PROSPR program. It targets LINE-1 inhibition to slow aging-related diseases.
Latest Transposon Therapeutics News & Updates
See the latest news and media coverage for Transposon Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing therapies for neurodegenerative diseases
transposonrx.com- Headquarters
- San Diego, United States
- Founded year
- 2020
- Company type
- Private company
- Number of employees
- 10–50
- Industry
- Pharmaceuticals
Last updated
Latest news about Transposon Therapeutics
In short: Transposon Therapeutics received FDA Fast Track status for TPN-101 in PSP and secured $22M to study its effects on aging and healthspan.
Company announcements
Transposon receives ADDF investment for TPN-101 Alzheimer’s trial
Plans Phase 2 trial in Q4 2025, building on positive PSP and ALS results. Advances in HEALEY ALS trial.
Transposon Therapeutics announces TPN-101 inclusion
TPN-101 joins Phase 2/3 HEALEY ALS Platform Trial after promising Phase 2 results in C9orf72-related ALS.
Transposon Therapeutics presents Phase 2 results of TPN-101
Treatment shows clinical benefits on ALSFRS-R, SVC, and lowers NfL, IL-6 biomarkers at ALS/MND Symposium.
Media coverage
Transposon Therapeutics’ TPN-101 for Progressive Supranuclear Palsy Gets Fast Tracked | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The FDA granted fast track designation to TPN-101, an investigational therapy for progressive supranuclear palsy, based on promising phase 2a study results.
URochester researchers awarded up to $22M to study a hidden driver of aging
What if people could stay healthier, stronger, and mentally sharper as they grow older—not by treating diseases one by one but by slowing a biological...
Transposon Receives Investment From The Alzheimer's Drug Discovery Foundation To Support Advancement Of TPN-101 For The Treatment Of Alzheimer's Disease
Building on the positive results of Phase 2 clinical trials in PSP and ALS, Transposon plans to initiate a Phase 2 clinical trial of TPN-101...
Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS
News provided by Transposon Therapeutics May 28, 2025, 8:00 AM ET In the Phase 2 Study of TPN-101 in patients with C9orf72-related ALS, TPN-101 showed...
Never miss news about Transposon Therapeutics
Track Transposon Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Transposon Therapeutics competitors & trending companies
Browse news for competitors to Transposon Therapeutics and other trending companies.
Clene
Neurizon
Ionis
BioArctic
Nura Bio
Tiziana
Alzinova
Herantis Pharma
VectorY
NRG Therapeutics
Celosia
AL-S Pharma
uniQure
Sensorium
Trace Neuroscience
Amylyx
Neurimmune
Raya
Oculis
Ticketplus
HELP Therapeutics
CMC
ManpowerGroup
Arcosa
Alliance Entertainment
QXO
Reliant Stones
Amber
The Pool Tile Co
Cinajus
Armstone
Eco Outdoor
Sareen Stone
Stone Planet
Salience Labs